No Data
GoodRx Holdings: Strategic Shift Towards Branded Medications Amid Uncertain 2025 Outlook
A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $4.5 to $10
Morgan Stanley Adjusts GoodRx Holdings' Price Target to $7 From $9.50, Keeps Equalweight Rating
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Is Still Matching Investor Opinion Despite 28% Slump
Why GoodRx Holdings Stock Was Sinking This Week
GoodRx Holdings: Mixed Signals Prompt Hold Rating Amid Revenue Challenges and EBITDA Prospects
No Data
No Data